Profile data is unavailable for this security.
About the company
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
- Revenue in USD (TTM)0.00
- Net income in USD-258.08m
- Incorporated1999
- Employees268.00
- LocationRocket Pharmaceuticals Inc9 Cedarbrook DriveCRANBURY 08512United StatesUSA
- Phone+1 (646) 440-9100
- Fax+1 (781) 676-2155
- Websitehttps://www.rocketpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novavax Inc | 987.67m | -294.33m | 1.43bn | 1.54k | -- | -- | -- | 1.44 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Gyre Therapeutics Inc | 165.85m | -79.66m | 1.43bn | 593.00 | -- | 21.71 | -- | 8.63 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Praxis Precision Medicines Inc | 1.61m | -151.02m | 1.45bn | 82.00 | -- | 3.62 | -- | 904.31 | -10.29 | -10.29 | 0.1058 | 21.52 | 0.0061 | -- | -- | 19,573.17 | -57.75 | -74.04 | -63.81 | -85.12 | -- | -- | -9,409.22 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Travere Therapeutics Inc | 203.45m | -348.96m | 1.55bn | 380.00 | -- | -- | -- | 7.62 | -4.52 | -4.56 | 2.63 | -0.3909 | 0.3043 | 0.7192 | 10.24 | 535,386.80 | -52.19 | -36.95 | -69.25 | -44.77 | 95.21 | 95.92 | -171.52 | -165.79 | 1.68 | -- | 1.09 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -258.08m | 1.59bn | 268.00 | -- | 4.82 | -- | -- | -2.75 | -2.75 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -52.01 | -35.26 | -56.17 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0605 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| BioCryst Pharmaceuticals Inc | 412.58m | -123.82m | 1.61bn | 536.00 | -- | -- | -- | 3.91 | -0.6073 | -0.6073 | 2.01 | -2.26 | 0.8136 | 0.4297 | 6.54 | 769,736.90 | -24.42 | -47.95 | -32.17 | -64.89 | 98.06 | 97.06 | -30.01 | -114.94 | 2.73 | -0.488 | 2.29 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Arcus Biosciences Inc | 263.00m | -270.00m | 1.63bn | 577.00 | -- | 2.89 | -- | 6.21 | -3.15 | -3.15 | 3.06 | 6.17 | 0.2153 | -- | 6.83 | 455,805.90 | -22.10 | -15.85 | -26.63 | -18.25 | -- | -- | -102.66 | -103.46 | -- | -- | 0.0768 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Kiniksa Pharmaceuticals Ltd | 384.10m | -9.07m | 1.65bn | 297.00 | -- | 3.77 | -- | 4.30 | -0.1584 | -0.1584 | 5.28 | 6.06 | 0.7398 | 1.94 | 27.51 | 1,293,259.00 | -1.75 | -16.49 | -2.04 | -18.72 | 86.31 | -- | -2.36 | -53.64 | 2.95 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.65bn | 23.00 | -- | 7.67 | -- | 3,303.77 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Day One Biopharmaceuticals Inc | 101.95m | -84.29m | 1.65bn | 174.00 | -- | 2.97 | -- | 16.21 | -1.02 | -1.02 | 1.14 | 5.51 | 0.2009 | -- | -- | 657,761.30 | -16.61 | -- | -17.73 | -- | 97.75 | -- | -82.68 | -- | 14.55 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Xencor Inc | 85.16m | -198.24m | 1.65bn | 280.00 | -- | 2.28 | -- | 19.41 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Intellia Therapeutics Inc | 43.09m | -522.28m | 1.70bn | 526.00 | -- | 1.77 | -- | 39.44 | -5.45 | -5.45 | 0.4509 | 9.46 | 0.0357 | -- | 5.62 | 81,912.55 | -43.22 | -31.34 | -47.07 | -34.53 | -- | -- | -1,212.19 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Dynavax Technologies Corp | 249.70m | 17.18m | 1.70bn | 408.00 | 128.67 | 2.65 | 78.69 | 6.83 | 0.1011 | 0.1011 | 1.76 | 4.91 | 0.2557 | 0.7766 | 4.76 | 611,997.60 | 1.76 | 4.16 | 1.86 | 5.71 | 82.03 | 64.83 | 6.88 | 9.19 | 13.18 | -- | 0.2578 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Bicycle Therapeutics PLC (ADR) | 36.90m | -166.28m | 1.72bn | 284.00 | -- | 2.07 | -- | 46.71 | -3.28 | -3.28 | 0.7163 | 12.04 | 0.0451 | -- | 0.9806 | 129,922.50 | -20.33 | -29.45 | -22.03 | -32.98 | -- | -- | -450.64 | -571.36 | -- | -- | 0.0002 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Celldex Therapeutics, Inc. | 9.98m | -154.08m | 1.74bn | 160.00 | -- | 2.21 | -- | 174.37 | -2.57 | -2.57 | 0.164 | 11.85 | 0.0181 | -- | 18.07 | 62,350.00 | -27.93 | -29.65 | -29.53 | -31.42 | -- | -- | -1,544.48 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Data as of Nov 08 2024. Currency figures normalised to Rocket Pharmaceuticals Inc's reporting currency: US Dollar USD
65.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 30 Jun 2024 | 17.69m | 19.44% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 11.24m | 12.36% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.61m | 6.17% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.96m | 5.46% |
| Westfield Capital Management Co. LPas of 30 Jun 2024 | 4.33m | 4.76% |
| Maverick Capital Ltd.as of 30 Jun 2024 | 3.93m | 4.32% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 3.09m | 3.39% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 2.88m | 3.17% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.78m | 3.06% |
| Citadel Advisors LLCas of 30 Jun 2024 | 2.77m | 3.04% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
